Document is current
Any future updates will be listed below
-
Authors
Qiu, Yuqi
Jacobs, Diane M.
Messer, Karen
Salmon, David P.
Wellington, Cheryl L.
Stukas, Sophie
Revta, Carolyn
Brewer, James B.
Léger, Gabriel C.
Askew, Brianna
Donahue, Lia
Kaplita, Stephen
Coric, Vladimir
Qureshi, Irfan A.
Feldman, Howard H.
,
Obisesan, Thomas
Smith, Amanda
Heidebrink, Judith
Mintzer, Jacobo
Ala, Thomas
Pierce, Aimee
Schneider, Lon
Heidebrink, Judith
Bell, Karen
Nowrangi, Milap
Smith, Amanda
Jicha, Gregory
Lopez, Oscar
Porsteinsson, Anton
Jefferson, Angela
Farlow, Martin
van Dyck, Christopher
Grant, Ian
Siegal, Alan
Spann, Bryan
Atri, Alireza
Lerner, Alan
Scharre, Douglas
Miller, Del D.
Peskind, Elaine
Drake, Jonathan
Ritter, Aaron
Bernick, Charles
Richter, Ralph
Karathanos, Michael
Mintzer, Jacobo
Brawman-Mintzer, Olga
Baumel, Bernard
Keller, Jeffrey
Bozoki, Andrea
Sidiropoulos, Christos
Brangman, Sharon
Tchikindas, Olga
Bath, Kiran
Weisman, David
Singer, Clifford
Lichtenstein, Maya
Sano, Mary
Peters, James J.
Beyzer, Alexander
Shubin, Richard
McCallister, Peter
Flitman, Stephen
Verghese, Cherian
Seshadri, Sudha
Burke, Anna
Ross, Jeffrey
Brody, Mark
-
Funding
Funding for this research was provided by:
NIH/NIA (U19 AG010483, U19 AG010483, U19 AG010483, U19 AG010483, U19 AG010483, U19 AG010483, U19 AG010483, U19 AG010483)
Grant to UC San Diego from Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc.
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 20 April 2025
First Online: 2 May 2025
Declarations
:
: Trial oversight was provided by the central Institutional Review Board (IRB), Advarra. Written informed consent was obtained from study participants, legally authorized representatives, or study partners per IRB regulations in accordance with the Declaration of Helsinki and the Belmont Report.
: Not applicable.
: YQ is funded by National Natural Science Foundation of China (grant number 12401347), Chinese MOE Foundation on Humanities and Social Sciences (grant number 23YJC910006) and Shanghai Baiyulan Pujiang project (24PJD087). DMJ reports support from grants to UC San Diego from the NIH, Biohaven Pharmaceuticals, Vivoryon Therapeutics, and a philanthropic donation for the Epstein Family Alzheimer Research Collaboration. KM reports support from grants to UC San Diego from the NIH and Biohaven Pharmaceuticals. DPS reports support from grants to UC San Diego from the NIH and Biohaven Pharmaceuticals and consulting fees from Biogen and Aptinyx. CLW reports no disclosures. SS reports no disclosures. CR reports support from grants to UC San Diego from the NIH and Biohaven Pharmaceuticals. JBB reports support from grants to UC San Diego from the NIH and Biohaven Pharmaceuticals. GCL reports support from grants to UC San Diego from the NIH and Biohaven Pharmaceuticals. BA, LD, SK, VC, and IA are currently employed by Biohaven Pharmaceuticals, Inc. and own stock and hold stock options in Biohaven Pharmaceuticals, Inc. HHF reports grant funding from Biohaven Pharmaceuticals with no personal funds received and all payments to the Alzheimer's Disease Cooperative Study at UC San Diego. HHF also discloses grant funding from Annovis (QR Pharma), Vivoryon (Probiodrug), AC Immune, and LuMind Foundation; service agreements for consulting activities with LuMind, Axon Neuroscience, Novo Nordisk, Arrowhead Pharmaceuticals, Roche/Genentech Pharmaceuticals (DMC/DSMB), Tau Consortium (SAB), Janssen Research & Development (DSMB); support for travel from Novo Nordisk, Royal Society of Canada, and Translating Research in Elder Care (TREC); and a philanthropic donation for the Epstein Family Alzheimer Research Collaboration. For these activities, no personal funds have been received with all payments to UC San Diego. HHF personally receives royalties for patent: Feldman HH (filed November 26, 2008). Detecting and Treating Dementia Serial Number 12/3-2691 U.S. Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office.
